Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$50.34
-0.9%
$44.31
$32.00
$54.23
$2.49B0.95480,875 shs737,624 shs
Organogenesis stock logo
ORGO
Organogenesis
$3.23
-1.2%
$3.68
$2.28
$6.71
$409.73M1.631.14 million shs1.49 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$20.46
-2.8%
$23.72
$16.60
$28.47
$1.50B1.64904,558 shs1.40 million shs
Vericel Corporation stock logo
VCEL
Vericel
$42.02
+0.6%
$41.44
$37.39
$63.00
$2.12B1.33411,353 shs610,187 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
0.00%+1.43%+14.41%+7.06%+57.07%
Organogenesis stock logo
ORGO
Organogenesis
0.00%+5.21%+11.38%-40.41%+29.20%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
0.00%-4.53%-4.39%-10.07%+8.95%
Vericel Corporation stock logo
VCEL
Vericel
0.00%-1.52%+2.69%-12.35%-6.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.8738 of 5 stars
3.61.00.04.22.51.70.6
Organogenesis stock logo
ORGO
Organogenesis
4.5812 of 5 stars
3.33.00.04.33.84.20.6
Schrodinger, Inc. stock logo
SDGR
Schrodinger
1.9273 of 5 stars
3.51.00.00.01.12.50.6
Vericel Corporation stock logo
VCEL
Vericel
2.2846 of 5 stars
3.51.00.00.01.40.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.13
Buy$65.5030.12% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5070.28% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
3.00
Buy$32.8060.31% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1445.51% Upside

Current Analyst Ratings Breakdown

Latest ORGO, VCEL, MIRM, and SDGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/19/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$73.00
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.00
5/9/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00
4/16/2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.00
4/11/2025
Vericel Corporation stock logo
VCEL
Vericel
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$61.00 ➝ $51.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$336.89M7.40N/AN/A$4.70 per share10.71
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.85$0.21 per share15.48$2.09 per share1.55
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$207.54M7.23N/AN/A$5.78 per share3.54
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.92$0.31 per share134.47$5.92 per share7.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$187.12M-$2.63N/AN/AN/A-83.39%-44.74%-26.29%7/30/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,401.1395.50N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest ORGO, VCEL, MIRM, and SDGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/7/2025Q1 2025
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.81-$0.82-$0.01-$0.82$54.60 million$59.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.32
3.22
3.04
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
3.45
3.45
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
22.87%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8.60%
Vericel Corporation stock logo
VCEL
Vericel
7.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14049.53 million38.21 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79073.38 million67.07 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million46.72 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$50.34 -0.46 (-0.91%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$50.37 +0.03 (+0.06%)
As of 06/20/2025 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.23 -0.04 (-1.22%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.28 +0.04 (+1.39%)
As of 06/20/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$20.46 -0.59 (-2.80%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$20.66 +0.20 (+0.98%)
As of 06/20/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Vericel stock logo

Vericel NASDAQ:VCEL

$42.02 +0.24 (+0.57%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$42.05 +0.03 (+0.07%)
As of 06/20/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.